EUVIMEDEUVIMED entdecken
Qualitative StudieOpen Access · CC BY 4.0

‘Patients are left not knowing’: Trastuzumab (Herceptin) cardiac risk information and management in HER2-positive breast cancer—a qualitative study of patient experience

Karina Dolgilevica, Bethany Chapman, Nazanin Derakshan

Supportive Care in Cancer · 2026-03 · 34 (3)

DOI: 10.1007/s00520-026-10357-y ↗

Kurz gefasst

Qualitative Studie in der Zeitschrift Supportive Care in Cancer, online erschienen am 05.02.2026. Verfasst von Karina Dolgilevica und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Psychological Sciences, Birkbeck University of London, London, UK. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Breast Neoplasms, Cardiotoxicity, Health Knowledge, Attitudes, Practice. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The current study investigated the extent of knowledge and care regimen regarding the possible risks of cardiac dysfunction from Trastuzumab (Herceptin) treatment in women with either a diagnosis of primary or metastatic breast cancer who had undergone or were receiving Trastuzumab at the time of the study.

Method

In a qualitative interview, participants were asked questions regarding awareness of cardiac risks of Trastuzumab therapy and knowledge of cardiac damage symptoms, as well as questions concerning the regimen of heart function monitoring during and beyond their course of treatment. Thematic analysis was used to analyse the data.

Results

The emerging themes from the thematic analysis revealed inconsistencies in (a) knowledge and awareness of cardiac damage risk prior to taking Trastuzumab, (b) monitoring of cardiac function and risks of cardiac dysfunction during and beyond treatment, and (c) awareness of signs of possible cardiac damage of Trastuzumab during treatment.

Conclusions

Our results suggest that patients feel unsupported and ill-informed about the possible risks of cardiac damage from Trastuzumab. This has implications for the self-management of symptoms and mitigation of risks for cardiac damage and suggests the need for improvement in patient care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalBreast NeoplasmsCardiotoxicityHealth Knowledge, Attitudes, PracticeTrastuzumabAdultFemaleHumansMiddle AgedHeart Disease Risk FactorsQualitative ResearchGenes, erbB-2Erb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

Breast cancerCardiac dysfunctionHerceptinPatient experienceQualitative method

Substanzen

Antineoplastic Agents, ImmunologicalTrastuzumabERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • School of Psychological Sciences, Birkbeck University of London, London, UK.
  • School of Psychology and Clinical Language Sciences, University of Reading, Reading, UK.
  • School of Psychology and Clinical Language Sciences, University of Reading, Reading, UK. drnazaninderakshan@ncio.org.uk.
  • National Centre for Integrative Oncology (NCIO), Reading, UK. drnazaninderakshan@ncio.org.uk.

Zitieren

APA

Dolgilevica, K., Chapman, B., & Derakshan, N. (2026). ‘Patients are left not knowing’: Trastuzumab (Herceptin) cardiac risk information and management in HER2-positive breast cancer—a qualitative study of patient experience. Supportive Care in Cancer, 34(3). https://doi.org/10.1007/s00520-026-10357-y

Vancouver

Dolgilevica K, Chapman B, Derakshan N. ‘Patients are left not knowing’: Trastuzumab (Herceptin) cardiac risk information and management in HER2-positive breast cancer—a qualitative study of patient experience. Supportive Care in Cancer. 2026;34(3). doi:10.1007/s00520-026-10357-y

BibTeX
@article{Dolgilevica2026,
  author = {Dolgilevica, Karina and Chapman, Bethany and Derakshan, Nazanin},
  title = {‘Patients are left not knowing’: Trastuzumab (Herceptin) cardiac risk information and management in HER2-positive breast cancer—a qualitative study of patient experience},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {3},
  doi = {10.1007/s00520-026-10357-y}
}
Kostenlos starten →